We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Drugmaker will ‘fill and finish’ as-yet-unapproved jabs as talks continue over EU export controls
Moncef Slaoui forced out as chair of the board of drugmaker’s subsidiary Galvani Bioelectronics
Faith in monoclonal antibodies pays off with promising results
Data from 583 patients shows 85% reduction in hospitalisation or death
New vaccine producers and mRNA technology are shaking up the market
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Cynthia Carroll joins Glencore board, Bezos to step aside
€150m deal aims to have a vaccine ready for use in 2022
Pharma giant to co-lead funding round for Cambridge biotech start-up Adrestia
European partnership hit by dosage issues while Canberra project is derailed by false positive HIV tests
Pharma group’s new buzz phrase is ‘net positive impact on nature’
UK group says treatments for diseases other than Covid-19 have picked up after lockdown disruption
Governments must resist the urge towards protectionism
Washington will pay up to $2.1bn to speed up development and secure an initial 100m doses
UK drugmaker says earnings forecast will be under threat unless immunisation rates pick up
Both companies stand to benefit from the spotlight on immunisation
Advance purchase agreement depends on clinical trials starting in September
Waiting on turnround at GSK; waiting on court decision over business interruption insurance
Deal increases UK drugmaker’s exposure to potential coronavirus vaccines
Covid-19 is a warning that we must develop drugs to treat future threats
Study with 4,566 people found cabotegravir is more effective than current care standard
Drugmaker says adjuvant would allow for more doses and offer longer-lasting immunity
With new cancer drugs and a vaccines partnership with Oxford university, AZ’s turnround has boosted the industry in Britain
Investors say competition needs to be put aside for the greater good
Rival drugmakers both hold ‘piece of the puzzle’, says David Loew
International Edition
